转录组分析揭示系统性红斑狼疮治疗应答的分子基础
研究对92例活动性SLE患者基线及治疗6个月后(32例配对样本)血液行RNA测序,治疗包括环磷酰胺40例、利妥昔单抗20例、贝利尤单抗23例、吗替麦考酚酯8例、硫唑嘌呤1例;应答以狼疮低疾病活动状态定义。应答者基线B细胞免疫及补体激活相关特征升高,有效治疗可逆转B细胞免疫特征;环磷酰胺独特下调中性粒细胞活化通路;539基因特征与治疗应答不足相关。
要点
- 应答者基线B细胞免疫和补体激活相关转录特征升高,有效治疗可逆转B细胞免疫特征。
- 利妥昔单抗对B细胞通路活性降低最显著,环磷酰胺独特下调中性粒细胞活化通路。
- 539基因特征富集趋化因子信号过程,可区分治疗应答不足的患者。
核心结论
- 基线B细胞免疫转录特征与有利治疗结局相关,可解释血清学活动患者应答更佳,有效治疗可逆转该特征。
- 环磷酰胺独特靶向与重型SLE相关的中性粒细胞基因特征。
- 趋化性改变可能是驱动SLE治疗抵抗的机制。
研究设计与样本
- 对92例活动性SLE患者基线及治疗6个月后(32例配对样本)血液行RNA测序。
- 治疗包括环磷酰胺40例、利妥昔单抗20例、贝利尤单抗23例、吗替麦考酚酯8例、硫唑嘌呤1例。
- 应答以狼疮低疾病活动状态定义,识别差异表达基因与共表达转录模块。
主要发现
- 无论何种治疗,达到应答均伴随B细胞免疫相关和补体激活相关特征的 downregulation。
- 利妥昔单抗导致B细胞通路活性降低最显著,环磷酰胺独特下调中性粒细胞活化通路。
- 应答者无论用药,治疗前中性粒细胞迁移、I型干扰素信号、补体激活和B细胞功能相关通路活性升高。
- 539基因特征富集趋化因子信号相关过程,表征治疗应答不足的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterised by variable treatment responses. We investigated the transcriptional landscape associated with treatment response and resistance in SLE. METHODS: Blood was collected from 92 active patients with SLE at baseline and after 6 months (n=32 paired samples) of treatment with cyclophosphamide (n=40), rituximab (n=20), belimumab (n=23), mycophenolate mofetil (n=8) or azathioprine (n=1) and was subjected to RNA sequencing. The response was defined by the Lupus Low Disease Activity State. We identified differentially expressed genes and co-expressed transcript modules. RESULTS: Achieving response, irrespective of treatment, was accompanied by downregulation of B cell immunity-related and complement activation-related signatures. Rituximab led to the most profound decrease in the activity of the B cell pathway, while cyclophosphamide uniquely downregulated neutrophil activation pathways. Responders, regardless of medication, showed increased activity in pathways related to neutrophil migration, type I interferon signalling, complement activation and B cell function prior to treatment. A 539-gene signature, enriched in processes related to chemokine signalling, characterised patients with insufficient response to treatment. CONCLUSIONS: Baseline B cell immunity transcriptional signatures correlate with favourable treatment outcomes-accounting for better responses in serologically active patients in SLE clinical trials-with effective treatment reversing the B cell immunity signature. Cyclophosphamide uniquely targets a neutrophil gene signature linked to severe SLE. Alterations in chemotaxis may represent a mechanism driving resistance to treatment in SLE.
引用
- Garantziotis P, Moysidou GS, Kapsala N, et al. Transcriptome analysis to decipher the molecular underpinnings of response to treatment in systemic lupus erythematosus. RMD Open. 2025. PMID: 40081913. doi:10.1136/rmdopen-2024-005050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。